FNA News and Press, Paragon 28 Inc. From 02/16/23

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, March 2, 2023. The company...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stocks are showing signs of life in 2023. And if you have a tolerance for risk and are willing to look for stocks to trade, the small-cap sector is one area to find stocks to watch.  Historically, small-cap stocks t...

Paragon 28 ( NYSE: FNA ) prices underwritten public offering of 6.5M shares at a public offering price of $17.00 per share. 3.75M shares are being offered for sale by Paragon and 2.75M shares are being offered for sale by certain selling securityholders. Underwriters a 30-...

Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the pricing of the previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering p...

Paragon 28 ( NYSE: FNA ) announced underwritten public offering of 6.5M shares, which would consist of 3.75M shares offered by Paragon and 2.75M shares offered by certain selling securityholders. Paragon and the selling securityholders also expect to grant the underwriters a 30-da...

Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the commencement of a proposed underwritten public offering of 6,500,000 shares of its common stock, consisting of 3,750,000 shares...

Paragon 28 ( NYSE: FNA ) expects Q4 revenue to be in a range of $51.2M to $51.5 million, representing reported growth of ~20% Y/Y, vs consensus of $49.56M . These results reflect foreign currency headwinds which are expected to reduce preliminary unaudited 4Q22 net revenue...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2022...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the 34 th Annual Piper Sandler Healthcare C...

Paragon 28, Inc. (FNA) Q3 2022 Earnings Conference Call November 10, 2022, 04:30 PM ET Company Participants Matt Brinckman - IR Albert DaCosta - Co Founder, President and Chief Executive Officer Stephen Deitsch - Chief Financial Officer Conference Call Part...